| Multiple Myeloma
Empliciti vs Aphexda
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Empliciti vs Aphexda with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAphexda has a higher rate of injection site reactions vs Empliciti based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Aphexda but not Empliciti, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Empliciti
Aphexda
At A Glance
IV infusion
Weekly to every 4 weeks
SLAMF7 antagonist
SC injection
Per apheresis (up to 2 doses)
CXCR4 inhibitor
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma (with lenalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly for cycles 1 and 2 (28-day cycles), then 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.
Multiple Myeloma 1.25 mg/kg via slow SC injection 10 to 14 hours before first apheresis, following 4 days of filgrastim pretreatment; premedicate with diphenhydramine, an H2 blocker, and a leukotriene inhibitor 30 to 60 minutes before each dose; a second dose may be given 10 to 14 hours before a third apheresis if necessary.
Contraindications
—
- History of serious hypersensitivity reactions to motixafortide
Adverse Reactions
Most common (>=10%) Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia, pain in extremities, headache, vomiting, weight decreased, lymphopenia, cataracts, oropharyngeal pain
Serious Pneumonia, pyrexia, respiratory tract infection, anemia, pulmonary embolism, acute renal failure
Most common (>20%) Injection site reactions (pain, erythema, pruritus), pruritus, flushing, back pain
Serious Vomiting, injection site reaction, hypersensitivity reaction, injection site cellulitis, hypokalemia, hypoxia
Pharmacology
Elotuzumab is a humanized IgG1 monoclonal antibody that targets SLAMF7 on myeloma cells and natural killer (NK) cells, directly activating NK cells through the SLAMF7 pathway and mediating killing of myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Motixafortide is a CXCR4 inhibitor that blocks binding of SDF-1alpha/CXCL12 to CXCR4, disrupting stem cell anchoring in the bone marrow and mobilizing hematopoietic stem and progenitor cells into the peripheral circulation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Empliciti
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Aphexda
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Empliciti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Aphexda
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Empliciti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Aphexda
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
BioLineRx Connect Patient Assistance Program: AphexdaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmplicitiView full Empliciti profile
AphexdaView full Aphexda profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.